Results 21 to 30 of about 28,270 (206)

Bivalirudin started during emergency transport for primary PCI. [PDF]

, 2013
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
Berg, J. van den, Bernstein, D., Clayton, T., Clemmensen, P., Coste, P., Deliargyris, E.N., Eggink, G.J., et al., Goldstein, P., Grunsven, P. van, Hamm, C.W., Hamon, M., Hof, A. van't, Huber, K., Lapostolle, F., Nef, H., Nibbe, L., Orto, M. Campo dell', Pocock, S., Prats, J., Schuette, D., Soulat, L., Steg, P.G., Steinmetz, J., Verheugt, F.W.A., Zeymer, U.   +25 more
core   +1 more source

Coming safely to a stop : a review of platelet activity after cessation of antiplatelet drugs [PDF]

, 2015
Funding Isobel Ford is an employee of the University of Aberdeen. The research for the writing of this review received no specific grant from any funding agency in the public, commercial, or not-forprofit sectorsPeer ...
Ford, Isobel
core   +1 more source

Systematic review and meta-analysis of optimal P2Y₁₂ blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome [PDF]

, 2016
Background: Patients with diabetes are at increased risk of acute coronary syndromes (ACS) and their mortality and morbidity outcomes are significantly worse following ACS events, independent of other comorbidities.
Brown, Oliver I, Hoye, Angela, Rossington, Jennifer A   +2 more
core   +2 more sources

Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome [PDF]

, 2019
Objective: To assess whether cardiovascular events are increased after cessation of dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) and to explore predictors for recurrent events after DAPT cessation during long-term follow-up.
Berry, Colin, Dawson, Jesse, Mazlan-Kepli, Wardati, Walters, Matthew   +3 more
core   +1 more source

A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor. [PDF]

PLoS ONE, 2015
Abnormal expression of thymic stromal lymphopoietin (TSLP) and its receptor (TSLPR) was found in patients with acute coronary syndrome. Ticagrelor, an oral platelet ADP P2Y12 receptor antagonist, is widely used in these patients.
Yi Mao, Yudong Peng, Qiutang Zeng, Longxian Cheng, Boyuan Wang, Xiaobo Mao, Kai Meng, Yuzhou Liu, Yitian Lian, Dazhu Li   +9 more
doaj   +1 more source

Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study

BMC Cardiovascular Disorders, 2020
Background Patients with coronary chronic total occlusion (CTO) require effective antiplatelet therapy after percutaneous coronary intervention (PCI). Ticagrelor has more pronounced platelet inhibition than clopidogrel. However, the most appropriate dose
Yong Wang, Hong-wei Zhao, Cheng-fu Wang, Xiao-jiao Zhang, Jie Tao, Chun-sheng Cui, Qing-kun Meng, Yu Zhu, De-feng Luo, Ai-jie Hou, Bo Luan   +10 more
doaj   +1 more source

Stroke following percutaneous coronary intervention : type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12 [PDF]

, 2016
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015.
Berry, Colin, British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research, Buchan, Iain, de Belder, Mark A, Keavney, Bernard, Kontopantelis, Evangelos, Kwok, Chun Shing, Ludman, Peter F, Mamas, Mamas A, Myint, Phyo K, Nolan, Jim, Zaman, Azfar   +11 more
core   +1 more source

Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1

Frontiers in Cardiovascular Medicine, 2023
Doxorubicin (Dox) is a widely used clinical drug whose cardiotoxicity cannot be ignored. Pyroptosis (inflammatory cell death) has gradually gained attention in the context of Dox-induced cardiotoxicity.
Shu-hui Wang, Meng-jin Sun, Si-yue Ding, Chun-li Liu, Jing-min Wang, Sheng-na Han, Xi Lin, Qian Li   +7 more
doaj   +1 more source

Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression [PDF]

, 2016
The P2Y12 antagonist ticagrelor reduces mortality in patients with acute coronary syndrome (ACS), compared with clopidogrel, and the mechanisms underlying this effect are not clearly understood.
Akhmedov, Alexander, Beer, Juerg H., Bonetti, Nicole R., Camici, Giovanni G., Gaul, Daniel S., Glanzmann, Martina, Keller, Stephan, Lüscher, Thomas F., Matter, Christian M., Reiner, Martin F., Ruf, Wolfram, Savarese, Gianluigi, Stivala, Simona, Yang, Zhihong, Zhu, Cuicui   +14 more
core   +1 more source

Unraveling the Pharmacokinetic Interaction of Ticagrelor and MEDI2452 (Ticagrelor Antidote) by Mathematical Modeling [PDF]

, 2016
The investigational ticagrelor-neutralizing antibody fragment, MEDI2452, is developed to rapidly and specifically reverse the antiplatelet effects of ticagrelor.
Almquist, Joachim, Gennemark, P., Goodman, J., Janefeldt, A., Madalli, S., Maqbool, S., Nylander, S., Pehrsson, S., Penney, M., Sandinge, A-S   +9 more
core   +1 more source